Overview

HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients

Status:
Completed
Trial end date:
2019-09-27
Target enrollment:
Participant gender:
Summary
This study will be conducted as a single-center, prospective, open-label, randomized trial that will evaluate adult patients admitted with septic shock to the medical critical care unit (MCC). The objective of the study is to determine if the use of hydrocortisone plus fludrocortisone is associated with a faster resolution of shock (defined as 24 hours vasopressor free) when compared to the use of hydrocortisone alone in medical, critically ill septic shock patients.
Phase:
Phase 2
Details
Lead Sponsor:
University of Tennessee Medical Center
Treatments:
Cortisol succinate
Fludrocortisone
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate